Revvity Hits a 52-Week High as Healthcare Stocks Slide
At Baird’s conference, Revvity backed its H2 backlog conversion story.
At Baird’s conference, Revvity backed its H2 backlog conversion story.
Tokyo is the first proof Waymo’s model can cross a border. Ask what that franchise is worth to Alphabet over a decade.
Three straight quarters of gating at the HPS Corporate Lending Fund has opened a debate: orderly queue or early warning on floating-rate debt?
SIA shows July chip sales rose, while UBS sees memory volatility. Here’s how investors are reconciling them.
Apple held the Duo at $1,999, then leaned on the storage ladder. The December quarter is the test.
Revenue up 21% to $292.8 million with record free cash flow, yet cautious Q3 guidance erased nearly a fifth of the stock’s value overnight.
The del-desiran miss raises a question large-cap pharma investors dodge: how much of a share price is pipeline hope, and when does that hope become a liability?
Isar Aerospace reached orbit on its second flight. Here is why RKLB still has the stronger hand.
A record ¥1 trillion retail bond at 4.75% shows how Son is funding a giant AI bet.
Wednesday’s earnings arrive six days after GPT-6 Astra crossed a threshold that makes identity governance more urgent than ever.